DDRE-03. INTERNATIONAL PRECLINICAL DRUG DISCOVERY AND BIOMARKER PROGRAM INFORMING AN ADOPTIVE COMBINATORIAL TRIAL FOR DIFFUSE MIDLINE GLIOMAS
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-oncology"
DOI: 10.1093/neuonc/noaa215.248
Abstract: DMG-ACT (DMG- multi-arm Adaptive and Combinatorial Trial) aims to implement a highly innovative clinical trial design of combinatorial arms for patients with diffuse midline gliomas (DMGs) at all disease stages that is adaptive to pre-clinical… read more here.
Keywords: drug; combinatorial trial; onc201 onc206; diffuse midline ... See more keywords
Abstract 2671: Imipridones ONC201 and ONC206 reduce expression of neogenin and EZH1/2 which correlate with synergy following their combination with EZH1/2 or HDAC inhibitors in treatment of DMG and other tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2671
Abstract: Imipridones are a family of small molecule compounds including ONC201, ONC206 and ONC212 with anti-cancer activity mediated in part through activation of the integrated stress response, induction of TRAIL and its receptor, DR5, and activation… read more here.
Keywords: onc201 onc206; dmg; combination; hdac inhibitors ... See more keywords
Abstract 4914: Role of ClpP in the anti-cancer effects of imipridone ONC201 and ONC206
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4914
Abstract: ONC201 is the first bitopic dopamine receptor D2 (DRD2) antagonist and allosteric mitochondrial protease ClpP agonist. Downstream of target engagement, ONC201 activates the integrated stress response pathway resulting in selective tumor cell death. ONC201 is… read more here.
Keywords: onc201 onc206; onc201; clpp; cell lines ... See more keywords